A meta-analysis of clinical trials found that psilocybin significantly reduces symptoms of depression and anxiety compared to control conditions, with low to moderate heterogeneity across studies and no detected publication bias. The effect was observed in short, medium, and long-term time frames. However, the evidence remains preliminary; larger and longer trials are needed before psilocybin could be approved for community use.
After decades of research restrictions, psychedelics are being reexamined as potential treatments for difficult-to-treat mental illnesses. They are generally considered physically safe and rarely lead to addiction. The Controlled Substances Act of 1970 classified psychedelics as Schedule I drugs. This review highlights the prospective use of psilocybin, LSD, MDMA, and ayahuasca for conditions such as treatment-resistant depression, post-traumatic stress disorder, end-of-life anxiety, and substance misuse disorders. Evidence from both animal and human studies suggests these substances may offer revolutionary treatments, but their history and potential for abuse require careful regulation to ensure they are used as effective medical treatments rather than drugs of abuse.